rivaroxaban, and by 75% in those receiving enoxaparin (edoxaban results not reported). Among the 249 patients who could be evaluated for hemostatic efficacy, 82% were judged to have good or excellent efficacy at 12 hours, with the great majority judged to be excellent. Efficacy was similar for intracranial and GI bleeding. There was no significant correlation between hemostatic efficacy and the reduction in antifactor Xa activity. Thus a change in anti-factor Xa activity is not likely to be useful for predicting clinical response.
Mild-to-moderate infusion reactions occurred in 2 patients, and no patient developed antibodies to factor X or Xa or to andexanet. During the 30 days post treatment, 34 patients (10%) experienced a thrombotic event and 49 patients (14%) died, 35 of cardiovascular causes.
Discussion:
Acute major bleeding associated with factor Xa inhibitors is a medical emergency often associated with a poor prognosis. There are limited treatment options for these episodes. The present results suggest that reversal with andexanet alfa is both safe and effective. 
New Generic Valsartan Approved
The FDA has approved a new generic version of the angiotensin II receptor blocker (ARB) valsartan to treat high blood pressure and heart failure. The prioritized review and approval of the new generic is an attempt to help reduce the current valsartan shortage, which occurred due to multiple recalls because of nitrosamine impurities found in the products. Prior to the approval, the FDA evaluated the manufacturing processes and also made sure the manufacturer used appropriate testing methods to demonstrate that the valsartan product does not contain nitrosamine impurities. The agency has helped facilitate manufacturing process changes that will produce ARBs that are free of nitrosamine impurities and will continue to work with generic manufacturers so that more agents without these impurities can be approved. FDA News Release: FDA approves a new generic valsartan : Agency prioritizing review of ARB applications to help mitigate shortage of valsartan. Available at www.fda.gov/NewsEvents/Newsroom/Press Announcements/ucm633255.htm.
Amphetamine XR Suspension
Results of a pilot study indicate that amphetamine extended-release oral suspension (AMPH EROS; Dyanavel) can produce positive effects as early as 30 min post dose in young patients with ADHD. 1 Background: AMPH EROS was approved in 2015 for treatment of ADHD, based on a placebo-controlled laboratory classroom study that showed an onset of action by 1 hour post dose, the earliest time point assessed.
Methods: Study subjects were 18 children, aged 6-12 years, with ADHD. AMPH EROS was initiated, and the dosage optimized over the first study week. After a practice laboratory classroom session, children were randomly assigned to receive AMPH EROS at a fixed dosage of 15, 17.5, or 20 mg/day or placebo in a randomized, crossover sequence for 2 additional classroom sessions, separated by 5 days. The onset of drug action was assessed as the change in score on the Swanson, Kotkin, Agler, M-Flynn, and Pelham Combined (SKAMP-C) rating scale from pre dose to 30 min post dose, relative to placebo.
Results:
The study met its primary efficacy endpoint, with greater changes in the SKAMP-C score from pre dose to 30 min post dose with AMPH EROS, relative to placebo (6-point improvement, vs 2.5-point deterioration with placebo; effect size,* 0.95; p<0.0118). AMPH EROS was also superior to placebo at 3 hours post dose (effect size, 1.57; p=0.0002). Change in the Permanent Product Measure of Performance, a written math test and secondary study endpoint, did not differ between AMPH EROS and placebo at 30 min, but did differ at 3 hours. During the study, patients were exposed to medication for 11 to 13 days. Three children reported fatigue, 2 reported decreased appetite, and none experienced insomnia.
Discussion:
The ideal action profile for an ADHD medication would be a single-dose agent with a rapid onset of action and an extended duration of effect, sustained into the early evening. Results of this study, although preliminary, support the suggestion of an early onset of action of AMPH EROS. Previous research has shown the agent has demonstrated efficacy for up to 13 hours post dose. 
MMR Vaccine and Autism
A large, population-based cohort study confirms previous findings that the measles, mumps, rubella (MMR) vaccination does not increase risk of autism in children. The study also did not support other concerns of vaccination critics: that MMR vaccines trigger autism in susceptible subgroups or that it leads to clusters of cases with onset shortly after vaccination.
Methods:
The nationwide cohort study included all children born in Denmark between 1999 and 2010. In Denmark, MMR vaccination is voluntary and provided free of charge; it is offered initially at age 15 months. The analysis was adjusted for many autism risk factors, and an autism risk score based on various pre-and perinatal factors was used to stratify cohort members into 10 risk deciles.
Results:
The cohort included >657,000 children. After excluding those who died, emigrated, or were later diagnosed with a genetic abnormality related to autism, the remaining 651,000 were followed until the end of the study. More than 95% of children received a first MMR vaccine, at a median age of 1.34 years. A total of 6517 children received a diagnosis of autism (mean age at diagnosis, 7.2 years), for a calculated rate of 130 per 100,000 person-years.
MMR vaccination was not associated with elevated risk of autism in the entire cohort or in any patient subgroup. Moreover, in 2 subgroups-girls and children born between 1999 and 2001-vaccination was associated with significantly reduced risk of autism. Hazard ratios were not elevated in boys, other birth subcohorts, children who received other early childhood vaccinations, those at high risk, or children with siblings with autism.
Discussion:
Since the now-retracted article linking MMR vaccination with autism, no study or meta-analysis has confirmed an association. The present study, by far the largest to date, confirms the lack of association and extends the findings to various subgroups. 
Oral Testosterone Approval
An oral testosterone undecanoate capsule (Jatenzo) has received FDA approval for the treatment of hypogonadism due to genetic disorders such as Klinefelter syndrome or tumors in men that have damaged the pituitary gland. In a clinical trial, 87% of men who received Jatenzo achieved an average testosterone level within the normal range. Common adverse effects in the trial included headache, an increase in hematocrit, a decrease in high-density lipoprotein cholesterol, high blood pressure, nausea, and an increase in prostate specific antigen (PSA). Treated patients should undergo regular monitoring of hematocrit, cholesterol, and PSA. Men with benign prostate hyperplasia should be monitored for worsening of symptoms.
Jatenzo should not be used in men with agerelated hypogonadism. In these patients, the benefits of Jatenzo do not outweigh the risks of treatment, particularly blood pressure increases that can raise the risks of heart attack, stroke, and cardiovascular death. The drug labeling will include a boxed warning about these effects.
FDA News Release: FDA approves new oral testosterone capsule for treatment of men with certain forms of hypogonadism. Available at www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ ucm63 4585.htm.
